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ABSTRACT 
Individuals with attention-deficit hyperactivity disorder (ADHD) and comorbid substance use 
disorder (SUD) comprise a significant group of patients displaying various degrees of 
personal suffering, entailing a substantial economical burden on society and presenting with 
challenges in treatment. The overlap between the two disorders is well established, but the 
underlying genetic and environmental mechanisms of their coexistence, are poorly 
understood. Furthermore, little is known about the effectiveness and safety of stimulant 
medication when ADHD and SUD coexist.  
This thesis aimed to investigate the etiological relationship between ADHD and substance 
use problems (Studies I and II) and to explore doses of, and adherence to, pharmacological 
treatment for ADHD in the presence of SUD (Studies III and IV). 
Quasi-experimental methods (Study I) were used to investigate whether smoking during 
pregnancy (SDP) is causally associated with ADHD in offspring. A family design (Study II) 
was applied to explore whether the overlap between ADHD and SUD arises from shared 
familial factors or is better explained by harmful effects of ADHD medication. Nationwide 
population-based cohort designs (Study III) were used to explore differences in and 
development of methylphenidate (MPH) doses in ADHD patients with and without SUD, and 
the impact of MPH doses on adherence to treatment in individuals with SUD (Study IV). 
The results show that the increased risk for ADHD in individuals exposed to SDP was 
attenuated when familial factors were accounted for, suggesting that genetically transmitted 
factors explain the association. Furthermore, genetic relatedness to an ADHD proband 
predicts SUD in ADHD-free relatives suggesting that the co-occurrence of ADHD and SUD 
may be due to common genetic factors shared between the two disorders. The studies 
focusing on stimulant treatment show that patients with comorbid SUD are prescribed higher 
MPH doses and have higher adherence to MPH treatment compared to patients with ADHD 
only. In both groups MPH doses stabilized within two years of treatment. Higher doses of 
MPH were associated with increased adherence to treatment. 
In conclusion, the collective findings from this thesis suggest that ADHD and SUD share 
common genetic underpinnings, that individuals with comorbid SUD receive higher 
stimulant doses than individuals with ADHD only, without signs of tolerance, and that 
stimulant doses predict adherence to pharmacological treatment in individuals with comorbid 
SUD. 
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1 INTRODUCTION 
It is well established that attention-deficit hyperactivity disorder (ADHD) and substance use 
disorders (SUD) frequently coexist (1, 2). Individuals with ADHD and comorbid SUD are a 
large group of patients often experiencing great personal sufferings, presenting with 
significant challenges in treatment and contributing to the economic burden on society (3). 
Despite the high comorbidity rates between ADHD and SUD (4), the genetic and 
environmental mechanisms underlying the overlaps are poorly understood. The central 
stimulant medication methylphenidate (MPH), the first choice for pharmacological treatment 
of ADHD, is effective and well tolerated in both children and adult with this condition (5, 6). 
However little is known about the efficacy and safety of MPH medication in individuals with 
comorbid SUD (7). As a consequence, the present clinical guidelines lack clear and 
consistent guidance on how this important and vulnerable group of patients should be treated 
(7-11).  
This thesis aims to expand the previous limited understanding in this field by addressing the 
following questions: 
a) How are ADHD and SUD etiologically related? 
b) Are stimulant medication prescription patterns different in individuals with ADHD and 
SUD compared to those with ADHD only?  
c) What factors influence adherence to stimulant treatment when ADHD and SUD coexist? 
The additional goal of addressing these clinically relevant questions using large scale national 
population-based registers, is to be able to impact policy making and clinical guidelines that 
are lacking today. Hopefully, the increased knowledge of common biological underpinnings 
will also contribute to the societal acceptance of these impairing diagnoses, as medically 
valid and treatable disorders. 
 
1.1 Attention Deficit Hyperactivity Disorder 
“Every humming fly, every shadow, every sound, the memory of old stories will draw him off his task to other 
imaginations. Even his own imagination, entertains him with a thousand minor subjects.” Melchior Adam 
Weikard 1775 
The earliest reference in medical literature of what we today refer to as ADHD, by the 
German physician, Melchior Adam Weikard, dates back to 1775 (12). Different theories 
regarding underlying etiological mechanisms and developmental trajectories as well as 
different treatment strategies for ADHD have been investigated and debated over the years. 
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The need for systematic classification and statistical information of psychiatric symptoms 
led to the parallel development of two major diagnostic classification systems during the 
1950s; the International Classification of Diseases (ICD) that in the sixth edition included a 
section on mental disorders and the Diagnostic and Statistical Manual of Mental Disorders 
(DSM).  
 
1.1.1 Diagnostic Assessment 
The ICD classification system is presented in its 10th edition (ICD-10) since 1997, preceded 
by previous Swedish versions, ICD-7 (1964-1963), ICD-8 (1969-1986) and ICD-9 (1987-
1996). The DSM, published by the American Psychiatric Association, is the standard 
classification of mental disorders used by mental health professionals in the United States. 
Each DSM diagnostic label is associated with a diagnostic code, derived from the ICD 
system. The studies included in this thesis were designed and conducted based on ICD 
diagnoses derived from the DSM-IV definition of ADHD, including three different subtypes; 
predominantly inattentive type, predominantly hyperactive/impulsive type and ADHD 
combined type (13). The combined type of ADHD represents a more severe form that bears 
the greatest resemblance to the ICD-10 diagnosis of hyperkinetic disorder.  
According to Swedish national guidelines, issued by The National Board of Health and 
Welfare (9), a diagnosis of ADHD in adulthood should be made by a specialist psychiatrist 
after a somatic and psychiatric evaluation including present and childhood history. Cognitive 
tests and assessments by a psychologist are recommended to chart and grade the specific 
areas of functional disabilities and impairment. Rating scales are often used as screening tools 
and supplementary support for the clinical interview. 
 
1.1.2 Prevalence  
ADHD is a common neurodevelopmental disorder affecting approximately 5-7% of children 
(14, 15) and 2.5% of adults (16, 17) worldwide. Public concerns that a shift in societal norms 
during the last decades may have contributed to the increase in prevalence rates of ADHD 
diagnoses, and as a consequence increased prescription rates of stimulant medication (18), are 
not supported by recent scientific literature (19, 20). The variability of prevalence estimates 
across different countries and time periods can instead be largely explained by specific 
methodological study characteristics (19, 21).  
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1.1.3 ADHD Across the Lifespan 
Contrary to what was earlier believed, many functional impairments of ADHD persist into 
adulthood and approximately two thirds of all children with ADHD will continue to be 
affected throughout life (22). The symptoms and impairment might be differently displayed 
depending on age and life context. Typically, symptoms associated with hyperactivity and 
impulsivity diminishes over the years whereas symptoms of inattention tend to be more 
constant (23). In order to be able to provide age and context appropriate treatment, it is 
important to acknowledge the trajectory of ADHD symptoms across the lifespan, and to 
adequately address the common co-diagnoses, including SUD, that occur in adulthood. 
In childhood, symptoms often become evident in the home or school environments. Children 
with ADHD more often experience failure in educational or academic settings (24), and poor 
or deviant social relationships (25) compared to same-aged children and un-affected siblings. 
Entering adolescence and early adulthood, the social and academic environment might 
become more complex and demanding, and the symptoms and impairment of ADHD can 
manifest into a plethora of adverse psychosocial outcomes. Young adults with ADHD often 
have a limited social circle (26), and are at increased risk of engaging in criminal activities 
and dropping out or being expelled from school compared to their peers (27). Importantly, 
exposure to substances of abuse becomes increasingly more common during the adolescent 
years (28) and having ADHD further increases the risk of early onset of substance abuse (29). 
The prevailing nature of ADHD is well established (30) and a majority of individuals with 
childhood ADHD will continue to experience less self-satisfaction in their personal and 
professional life (31) and are at increased risk of several adverse outcomes (31-33) including 
SUD (33) through the transition from adolescence into adulthood.  
 
1.1.4 Etiology 
The etiology of ADHD is still largely unknown. It is suggested that multiple genetic and 
environmental factors contribute to the age inappropriate and impairing symptoms of 
hyperactivity, impulsivity and inattention in affected individuals (34, 35). 
Family and twin studies show that ADHD runs in families, suggestive of a strong genetic 
predisposition (36) with over 75% of the variance of the disorder explained by genetic factors 
(37). However molecular genetic studies have failed to reproduce the consistently high 
estimates of genetic contribution found in observational research (38). Also, some genetic 
variants have been suggested to have pleiotropic effects across a broad range of diagnostic 
categories (39, 40), i.e. that the same genetic variants constitute risk factors for several 
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different disorders. Still, it is not clear to what extent ADHD shares etiological underpinnings 
with other major psychiatric disorders, including SUD.  
In addition to the strong genetic predisposition to ADHD, environmental factors account for 
an estimated 10% to 40% of the variance in liability to the disorder (35). Findings from 
imaging and pre-clinical studies have resulted in plausible biological theories indicating how 
exposure to addictive substances in utero may influence brain development (41, 42). Further, 
epidemiological studies have repeatedly, even after adjustment for measured confounders 
shown that maternal lifestyle factors are associated with ADHD in offspring (35, 43-46). In 
particular, maternal smoking during pregnancy (SDP), consistently associated with adverse 
offspring outcomes such as preterm birth and low birth weight (47), is often cited in the 
literature as an environmental risk factor for ADHD (48).  
 
1.1.5 ADHD Treatment 
It is well established that both non-stimulant (i.e. atomoxetine (ATX)) and central stimulant 
medication (i.e. MPH, amphetamine and/or dexamphetamine) effectively reduce the core 
symptoms of ADHD (49). Non-pharmacological treatment, most commonly cognitive 
behavioral-based interventions is an important component of the multimodal ADHD 
treatment approach and, according to a growing body of literature, best used as a complement 
to, not instead of, pharmacological treatment (50).  
 
Non-stimulant treatment 
Due to lack of abuse liability, non-stimulant treatment is often considered a safe and 
attractive treatment alternative when ADHD and SUD coexist (51). In fact, in the National 
Institute for Health and Care Excellence (NICE) guidelines for ADHD treatment in the 
presence of SUD or in high-risk individuals such as imprisoned populations, the selective 
noradrenaline (NA) reuptake inhibitor ATX is recommended as first-line therapy (11). 
Alpha-adrenergic agonists (clonidine and guanfacine) are approved for treatment of 
childhood ADHD in the US (but not in Sweden) and are shown to be efficacious in 
individuals with prominent symptoms of hyperactivity or aggression (52, 53). The evidence 
for the treatment of ADHD with other antidepressants, such as mixed catecholaminergic 
agents (e.g. bupropion), serotonin and noradrenaline reuptake inhibitors (e.g. venlafaxine), 
tricyclics (e.g. despiramine) or monoamine oxidase inhibitors (e.g. pargyline, deprenyl, 
selegeline), is limited at present (53). 
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Central Stimulant Treatment 
Stimulant medications act by increasing brain catecholamine levels (54) and are advocated as 
first line treatment for ADHD in both children and adults due to robust clinical efficacy (5, 
6, 8-11, 49, 55). Discrete increases in blood pressure and heart rate, insomnia, headache, 
abdominal pain and decreased appetite are relatively common side effects across all age 
groups (57, 58). However, the recent literature has not found evidence for increased risk of 
serious adverse events such as future SUD (59), suicidal behavior (60), psychotic episodes 
(61) or severe cardiovascular incidents (56). 
The optimal dose, both in adults and children, can vary considerably across individuals, 
regardless of baseline characteristics such as sex, age or weight (62). In clinical practice, a 
titration phase using successively increased doses while simultaneously following ADHD 
symptoms and possible adverse reactions via clinical assessments and rating scales is used to 
guide the optimal individual dose regime. Previous studies on MPH treatment in children 
show a need to increase doses to maintain treatment efficacy during the first year in treatment 
(63). Thereafter, the doses level off and stabilize. This phenomenon suggesting underlying 
mechanisms of tolerance to MPH treatment during the first year in treatment has however not 
been systematically investigated in adults. 
MPH is available as both immediate release (IR) and extended release (ER) formulations 
with different pharmacokinetic properties, differing in time to maximum serum concentration 
and behavioral effects (64, 65). IR formulations need to be administered twice or thrice a day 
and can thus entail challenges related to medication management (66). In order to avoid 
issues such as poor compliance, stigmatization of children having to re-administer medication 
during school hours and to reduce the abuse liability of MPH, ER formulations of MPH, such 
as the osmotic release oral system (OROS ®) are often recommended (67).  
 
1.2 Substance Use Disorder 
“They ask you about wine and gambling. Say: In them is great sin and yet, some benefit for 
people. But their sin is greater than their benefit." The Koran 2:219  
Humans have used substances with sedative, euphoric or hallucinogenic effects for religious, 
medical and recreational purposes throughout history (68). Opiates and alcohol are often used 
as typical models to study addiction since both substances, one illicit and the other one legal, 
induce the need to increase doses (tolerance), produce adverse physical symptoms when use 
is discontinued (withdrawal), and can create serious social, legal and professional 
consequences for the users (adverse psychosocial effects) (69). Some individuals will 
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progress from sporadic use, to dependence (70) but the environmental and genetic 
mechanisms behind these trajectories are far from completely understood. 
 
1.2.1 Diagnostic Assessments 
According to the ICD-10 and DSM-IV classification system, substance abuse or dependence 
syndromes are defined as behavioral, cognitive and physiological results of repeated 
substance use including a strong desire to take the drug, difficulties in controlling the use, 
persistent use despite harmful consequences, prioritizing drug intake over other activities and 
obligations, increased tolerance and physical withdrawal symptoms. The fifth edition of the 
Diagnostic and Statistical Manual of Mental Disorders (DSM-5) (71) published in 2013, no 
longer differentiates between substance abuse (i.e. predominantly negative social 
consequences) and dependence (i.e. predominantly negative physical and psychiatric 
consequences). Instead, DSM-5 applies a dimensional approach to problematic use of 
substances of abuse, defining the severity of the condition by a symptom count, requiring two 
or more symptoms from a list of 11, introducing the collapsed term substance use disorders 
(SUD). The criterion of substance-related legal problems used to define substance abuse has 
been removed, and an item related to craving is added. The studies included in this thesis use 
the ICD diagnoses of SUD based on the DSM-IV definitions of substance abuse and 
dependence.  
 
1.2.2 Prevalence  
Annual reports of the prevalence of alcohol and drug use disorders show a growing problem 
both in Sweden (72) and globally (70). According to worldwide estimations, almost 5%, i.e. 
246 million individuals, aged 15 to 64 used illicit drugs during 2013 (70). The health risks 
related to illicit drug use increase with the frequency and quantity of use and approximately 
10% of the users will experience medical or societal problems. While cannabis is the most 
frequently used illicit substance worldwide (70), it is opioid dependence that contributes to 
the highest rates of SUD related morbidity (73). According to WHO, 16% of adults that use 
alcohol will experience problematic use or dependence sometime during their lifetime. 
Furthermore, SUD is three times more common among men than women (70).  
 
1.2.3 Etiology 
SUD’s are chronic, highly genetically influenced disorders (74-76) with alternating relapses 
and remissions and specific neurobiological alterations (77). The high heritability estimates 
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shown in family-based research such as adoption (78, 79), and twin studies (80-83) have 
however not yet been replicated in molecular research (74). In addition, heritability 
estimates vary considerable between different studies suggesting that both shared and 
specific environmental factors may contribute to the multifactorial etiology of SUD. 
Adverse household factors such as abuse and maltreatment during childhood (84, 85), as 
well as prenatal factors such as in utero exposure to both alcohol and cigarette smoking have 
been associated with an increase risk for SUD and other severe externalizing behaviors (86, 
87). Importantly, the role of environmental risk factors does not contradict the genetic 
approach to addictive disorders. Previous research has shown that a specific gene makeup 
might increase vulnerability to certain disorders through these factors (88). For example, 
Cadoret et al. used an adoption study design to show that the presence of alcohol 
dependence in both biological and adoptive parents increased the risk for alcohol 
dependence in the adoptive children. However, alcohol dependence in the biological 
parents only increased the risk of externalizing behaviors in the adoptive child if the child 
was raised in a dysfunctional adoptive family (89). In line with such a hypothesis, 
suggesting that gene-environmental interactions needs to be taken into account when 
assessing the impact of environmental and genetic influences, Cloninger et al., arrived at 
similar conclusions in their adoption study of almost 900 Swedish men adopted by 
nonrelatives at an early age (90). Indeed, this study identified two forms of alcoholism that 
were differently affected by both genetic and environmental factors.  
In addition to genetic and environmental risk factors, cultural, religious and societal norms 
and political ordinances limiting consumption have historically influenced alcohol and drug 
use consumption (68). 
 
1.2.4 SUD Treatment  
Current treatment guidelines often recommend a combination of pharmacotherapy and 
psychosocial interventions (91). Cognitive behavioral therapy and other techniques based on 
enhancing individual motivation and reinforcing positive behavioral changes such as 
motivational interviewing, motivational enhancement therapy, brief intervention and 
community reinforcement approach have the strongest empirical support for SUD treatment 
(91, 92). 
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Pharmacological Treatment 
Pharmacological treatment of SUD has gained increased clinical recognition during recent 
years, focusing specifically on management of withdrawal symptoms, attenuation of craving, 
reduction of the rewarding effects of substances and prevention of relapse (93). Many of the 
current approved pharmacological substances for treatment of SUD are either full or partial 
agonists (e.g. methadone or buprenorphine for opiate dependence) acting as a substitution 
therapy, or antagonists (e.g. naltrexone for alcohol dependence) that specifically block 
receptors in the brain and in turn modulate the rewarding effects of the substance of abuse.  
 
1.3 When ADHD and SUD Coexist 
There is a robust association between ADHD and SUD. Individuals with ADHD are at 
increased risk of developing SUD (1) and the prevalence of ADHD among treatment seeking 
SUD patients is almost 25% compared to estimations of about 2.5% in the general adult 
population (4, 16, 17). Psychiatric disorders frequently coexist and might mimic symptoms 
of both adult ADHD (16) and SUD (94, 95), resulting in more severe impairments, worse 
prognosis (4, 95) and clinical challenges of utilizing pharmacological stimulant treatment in 
these individuals.  
A growing body of evidence from brain imaging research suggests similarities in ADHD and 
SUD pathophysiology (96). More specifically, dysfunction in dopaminergic transmission in 
cortical and subcortical pathways is associated with reduction in reward response and 
inhibitory control, implicated in both disorders (97-99). Indeed, many drugs of abuse, while 
having different molecular targets, have a common action of increasing dopamine 
transmission in cortical and subcortical areas of the brain (100). Long-term, chronic drug use 
results in down regulation of dopamine receptors and decreased dopamine function. These 
alterations in dopamine transmission might be related to the clinical phenomena of increased 
craving and loss of control, driving the individuals to compulsive drug intake to avoid the 
negative effects and symptoms of withdrawal (100). In addition, results from imaging studies 
show reduced dopamine receptor activity in subcortical brain areas of individuals with 
ADHD (101). This commonality in action has led to the view that the dopamine system plays 
a pivotal role in the neurobiology of both ADHD and SUD. This is of particular interest since 
the first line of pharmacological treatment for ADHD, namely stimulants (9-11, 55), operates 
by increasing dopamine levels in the same brain regions as those involved in addiction (54, 
99).  
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1.3.1 How are ADHD and SUD Etiologically Related? 
Previous research has found a robust association between ADHD and SUD, but the nature of 
this overlap has remained unclear. There are several alternative explanations for the high 
coexistence of ADHD and SUD. Firstly, the high degree of symptom overlap between the 
two disorders, including symptoms occurring in the context of intoxication or withdrawal of 
SUD, raises the question of whether the co-occurrence of ADHD and SUD in fact only 
represents a methodological artifact. Secondly, even though a growing body of studies 
suggests possible protective effects of ADHD medication on future development of SUD (59, 
102), there are still lingering concerns surrounding the risk of abuse or addiction related to 
MPH medication, based primarily on findings from animal and imaging studies (99, 103, 
104). Thirdly, in addition to research showing that prenatal exposure to maternal SDP is 
associated with several adverse pregnancy outcomes (47), studies have also suggested 
plausible biological mechanisms through which SDP may influence brain development (41, 
42). Given the robust association between SDP and ADHD in offspring observed in previous 
epidemiological studies, even after adjustment for measured confounders (35, 43-46), SDP is 
often suggested as a causal risk factor for ADHD. Thus, problems associated with SUD and 
ADHD may overlap across generations via the prenatal period. Importantly however, 
environmental exposures might also wrongfully be interpreted as causal risk factors when the 
increased risk actually arises due to familial confounding, such as genetically transmitted 
factors (105). Fourthly, there is an ongoing debate in the literature as to whether ADHD 
alone or externalizing disorders such as oppositional defiant disorder (ODD), conduct 
disorder (CD), and antisocial personality disorder (ASPD) that frequently co-occur with 
ADHD, mediate the increased risk of SUD (106-112). Either way, ADHD patients with CD 
tend to show more severe SUD symptoms compared to patients without a childhood history 
of coexisting ADHD and CD (112) suggesting that ADHD and CD interact synergistically, 
resulting in particularly severe forms of SUD (109). Fifthly, the overlap between ADHD 
and SUD may be explained by shared genetic risk factors. This is plausible given that both 
ADHD (36) and SUD (113) are highly heritable conditions. Previous family and twin studies 
have, nevertheless, produced inconsistent results regarding the nature of the coexistence of 
the two disorders (82, 114, 115). That is, some of the previous studies suggest shared genetic 
risk factors for ADHD and SUD (29, 116, 117), whereas other family-based studies indicate 
independent transmission of SUD and ADHD, or alternatively, the presence of an 
etiologically distinct ADHD plus SUD syndrome (118-120). Pleiotropic effects of genetic 
risk variants have been suggested across a broad range of psychiatric diagnoses (39, 40). This 
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in turn might indicate that the overlap of ADHD and SUD is unspecific and reflects genetic 
factors shared by several major psychiatric disorders and increasing the liability for 
psychiatric disorder in general.  
 
1.3.2 The Effectiveness and Safety of Stimulant Medication when ADHD and SUD 
Coexist 
Are stimulant medication prescription patterns different in individuals with ADHD and 
SUD compared to those with ADHD only?  
As noted earlier, stimulant medication is advocated as first line treatment for ADHD in both 
children and adults due to its robust clinical efficacy (5, 6, 8-11, 49, 55). On the other hand, 
we still have limited knowledge regarding several potential concerns, such as stimulant 
effectiveness, potential development of tolerance to MPH, and liability of non-medical use 
and abuse of stimulant medication in the comorbid SUD population. Given this substantial 
gap of knowledge regarding effective and safe treatment of coexisting ADHD and SUD, 
present clinical guidelines lack clear and consistent guidance on how this important and 
vulnerable group of patients should be treated (7-11).  
Since both adult ADHD (54), and SUD (121) have been linked to a dysregulation of brain 
dopamine and NA systems, this could hypothetically explain the therapeutic efficacy of 
catecholaminergic agonists such as stimulant drugs on ADHD. Subsequently, the same 
medications should theoretically be effective in treating SUD, regardless of impact on 
ADHD. However, drugs used to treat ADHD have not, in general, proven effective in the 
presence of comorbid SUD (7) and treatment guidelines for this population are 
consequently lacking. Nevertheless, the majority of studies on stimulant treatment of 
coexisting ADHD and SUD are limited by doses adjusted to suit individuals with ADHD 
only (7).  
Previous studies have shown a need for successively increasing MPH doses during the first 
year of treatment in children (63), but no previous population-based study has explored the 
extent to which individuals with ADHD and SUD are prescribed higher doses than 
individuals with ADHD only. Higher doses in the ADHD and SUD group would be 
expected if individuals with SUD due to neurobiological adaptations resulting from heavy 
drug use (100), developed tolerance not only to substances of abuse but also to 
pharmacological compounds such as MPH. Tolerance, a core sign of dependence might, in 
line with such an hypothesis and supported by results from neuroimaging research (123, 
124) lead to attenuated responses to stimulant medication resulting in the need for doses 
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exceeding those prescribed to drug naïve individuals.  
Another reason for expecting differences in doses between individuals with SUD and those 
with ADHD only, relate to the abuse potential of MPH. Given the risk of non-medical use of 
stimulants (125), and lack of clinical guidelines, clinicians might fear or suspect that patients 
feign ADHD symptoms in order to obtain stimulant medication (126). This in turn could 
influence a physician’s decision regarding individual dosing and possibly make him or her 
reluctant to prescribe adequate doses in patients with coexisting SUD.  
Tight societal controls are imposed on production and prescription of MPH for legitimate 
clinical use in accordance with Schedule II of the Controlled Substance Act in the US 
(127). In Sweden, MPH is classified among other narcotic medication with abuse potential 
and license to prescribe is restricted to physicians specialized in psychiatry, pediatric or 
neurology (128). To minimize the risk of abuse and diversion of stimulant medication, 
close supervision during initiation and titration phases of treatment periods is often 
encouraged. Short prescription intervals during the titration phase and before arriving at a 
stable dose are recommended. The clinical routines, in particular for individuals with 
comorbid SUD, typically involve evaluating and assessing the patient 1–3 times per week 
targeting changes in ADHD symptoms, adverse effects, cardiovascular monitoring and 
collecting of urine samples for laboratory analysis. The urinary analysis allows for 
detection of substances of abuse, which might or might not violate the treatment agreement 
and result in temporary treatment discontinuation. 
 
What factors influence adherence to stimulant treatment when ADHD and SUD coexist? 
Premature discontinuation of pharmacological treatment is a costly and medically 
significant problem (129) associated with worse treatment outcome (130-132). Adherence 
to psychopharmacological treatment in general is low and treatment for ADHD and SUD 
are no exceptions (133-135). In fact, a recent systematic review and meta-analysis of 
randomized controlled trials comparing MPH with placebo in adults with ADHD showed 
no advantage for MPH over placebo in terms of treatment discontinuation (136). One of the 
more consistent patient-related factors associated with treatment discontinuation in both 
ADHD and SUD is age. In particular, treatment discontinuation becomes increasingly 
common during the years of transition from child/adolescent to adult healthcare services 
(135, 137-139). Hypothetically, individual characteristics such as sex, SUD subtype and 
psychiatric comorbidity could influence both motivation and ability to adhere to 
pharmacological treatment. Previous research, however, is inconsistent in regard to what 
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factors might influence treatment adherence (132, 135, 137-139) and a recent meta-analysis 
investigating non-adherence to SUD treatment expressed great skepticism towards further 
exploration of demographic risk factors. Instead the authors highlight the need for potential 
treatment-related factors such as different treatment programs and treatment processes (135). 
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2 AIMS 
 
2.1 General Aims 
There were two overall aims for this doctorial project:  
Firstly, to use genetically informed epidemiological models to explore the etiological overlap 
between ADHD and SUD.  
Secondly, to use naturalistic cohort studies to explore the effectiveness and safety of 
stimulant medication when ADHD and SUD coexist.  
 
2.2 Study Specific Aims 
2.2.1 Study I and II 
Studies I and II aimed to explore how ADHD and SUD are etiologically related. In Study I 
the impact of familial (i.e. shared environment and genetic factors) confounding of the 
association between Smoking During Pregnancy (SDP) and ADHD in offspring was 
investigated. Study II explored whether common familial factors (i.e. environmental and 
genetic factors) were shared between the ADHD and SUD.  
 
2.2.2 Study III 
Study III first aimed to describe whether MPH prescription patterns were different in 
individuals with ADHD and SUD compared to those with ADHD only and whether MPH 
doses in both populations stabilized or increased after an initial titration interval. 
 
2.2.3 Study IV 
Study IV aimed to explore to what extent patient-related factors (i.e. age, sex, SUD subtype 
and psychiatric comorbidity) or treatment-associated factors (i.e. the prescribing physician’s 
(sub)specialty and MPH dose) influenced adherence to MPH treatment when ADHD and 
SUD coexist. 
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3  METHODS 
 
3.1 Data Sources 
Described in this section are the different Swedish registers used in the present thesis. 
 
3.1.1 The Personal Identification Number (PIN) 
Since 1947 the National Tax Board has assigned a unique, sex-specific, ten-digit personal 
identification number to all individuals resident in Sweden (birth or immigrated) (140). The 
ten digits represents, in order, the year, month and day of birth followed by a four-digit 
control number. The Swedish PIN covers the entire Swedish health care system and enables 
linkages between different population and medical registers. To ensure anonymity PIN’s 
were replaced by random index numbers by the authorities before delivery to the researchers. 
 
3.1.2 The National Patient Register (NPR) 
The NPR, held by The National Board of Health and Welfare since 1964, provides data on 
hospital discharge diagnosis according to the International Classification of Disorders (ICD-
codes). The register has complete coverage on psychiatric in-patient care since 1987 and 
registers outpatient public and private care since 2001. All Swedish county councils provide 
annual updates, however primary care is not yet covered in the NPR. Prior external register 
validations have shown 85-90% diagnose specific validity and low rates of dropout and 
missing data (141). 
 
3.1.3 The Swedish Prescribed Drug Register (PDR) 
The PDR, held by the National Board of Health and Welfare, provides almost complete 
coverage (0.3% missing data) on drug identity (Anatomical Therapeutic Chemical (ATC-
codes)) of all dispensed prescriptions to the entire population in Sweden since July 2005 
(142). 
 
3.1.4 The Medical Birth Register (MBR) 
The MBR is held by the Swedish National Board of Health and Welfare and provides 
information on all pregnancies (around 95,000 annually), deliveries and newborn infants in 
Sweden since 1973. Smoking during pregnancy (SDP) has been recorded since 1983 at the 
registration to antenatal care (in pregnancy week 8-12) (143, 144).  
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3.1.5 The Multi-Generation Register (MGR) 
The MGR is held by Statistics Sweden and contains information on over 13 million 
individuals by linking every individual born in Sweden since 1932 (the index person) to 
corresponding biological and adoptive parents (145). The register coverage is over 95% 
regarding parental status of index individuals born from 1932 onwards and alive on January 
1, 1961. For index individuals born outside of Sweden but immigrated before the age of 18 
the register coverage is comparable to Swedish-born individuals (145). 
 
3.1.6 The Cause of Death Register (CDR) 
The CDR is held by the Swedish National Board of Health and Welfare and provides 
information on all deceased Swedish citizens since 1958 and is considered to have almost 
complete coverage from 1961. The data contains date of death and ICD codes on main and 
contributory causes of death. In about 1-2% of the individuals in the CDR data on cause of 
death was missing (146). 
 
3.1.7 Database for Health Insurance and Labor Market (LISA) 
The LISA register is held by Statistics Sweden and contains annually updated information on 
education, employment and income of individuals over 16 years of age in each Swedish 
household since 1990. The database integrates existing data from the labor market, 
educational and social sectors and is updated each year with a new annual register (147). 
 
3.1.8 The Migration Register (MR) 
The MR is part of the Total Population Register (TPR) founded by Statistics Sweden in1968 
and includes information on dates of all registered migrations into or out of Sweden since 
1969.  
 
3.1.9 The Stockholm Child and Adolescent Psychiatric Care Register (Pastill) 
The Pastill Register covers information on psychiatric diagnoses based on both ICD-10 and 
DSM-IV codes for all children and adolescents living in Stockholm County since 2001. 
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3.2 Operationalization of Exposure and Outcome 
3.2.1 ADHD diagnosis 
ADHD was defined as an in- or outpatient diagnosis of Hyperkinetic Disorder (HKD) (F90 in 
ICD-10) between January 2001 and December 2009 from the NPR, and/or a diagnosis of 
HKD (F90 in ICD-10) or ADHD (DSM-IV:314) from Pastill (Study I), or a diagnosis of 
HKD (ICD-9: 314; ICD-10: F90) in the NPR (Study II). In addition, an individual was 
categorized as an ADHD case if he or she had received at least one prescription of a stimulant 
or non-stimulant medication for ADHD (ATC-code for methylphenidate (N06BA04); 
atomoxetin (N06BA09); amphetamine (N06BA01); dexamphetamine (N06BA02)) at any 
time between July 2005 and December 2009, identified from the PDR. 
 
3.2.2 SUD Diagnosis 
Information on SUD was acquired using both ICD-codes from the NPR and ATC-codes 
from the PDR (for drugs used exclusively in the treatment of SUD). Alcohol use disorder 
was defined using ICD-codes from the NPR (ICD-8: 291 and 303, ICD-9: 291, 303 and 
305A and ICD-10: F10.0-F10.9). The alcohol use disorder index from the PDR was based 
on ATC-codes for prescriptions of drugs used in the treatment of alcoholism (N07BB03 
(acamprosate), N07BB04 (naltrexone) and N07BB01 (disulfiram)). Psychoactive drug 
abuse was measured by ICD-codes from the NPR (ICD-8: 304, ICD-9: 292, 304 and 305X 
and ICD-10: F11.0-F16.9) and ATC-codes from the PDR (N02AE01 (buprenorphine), 
N07BC51 (buprenorphine+naltrexone) and N07BC02 (methadone)). 
 
3.2.3  Operationalization of MPH Doses and Treatment Periods 
Individual daily MPH doses were estimated by means of the text variable in the PDR. Each 
prescription contains a text variable stating the quantity of medication prescribed and 
individualized instructions on how the drug is to be consumed. A treatment period was 
defined as the number of days the prescription would last according to the text variable on the 
prescription, plus 25% of that time, to avoid individual minor irregularities in dispensing 
patterns. During subsequent periods or those without any new prescription, the patient was 
assumed to be off treatment. 
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3.3 Observational Study Designs 
Described in the section below are the different study designs used in the current thesis. 
An observational study draws inferences about a possible effect of an exposure, where the 
assignment of exposure status is beyond the control of the investigator. This is in contrast to 
randomized controlled trials (RCTs), where each subject is randomly assigned to an exposed 
group or a control group. A major challenge in observational research is to design the study 
and draw inferences that are acceptably free from influences by confounding or biases. 
However, observational studies have several advantages over experimental research 
including the possibility to study large samples representative of the general population over 
long periods of time at an affordable cost.  
Observational research might seem ideal to establish associations between exposures and 
outcomes. Nevertheless, an association or a correlation, however strong and convincing, does 
not equal causality. To make a judgment as to whether an exposure is causal or not several 
alternative explanations, such as chance, bias or confounding, must be considered, evaluated 
and eliminated.  
 
3.3.1 Cohort Studies 
All the studies included in this thesis are cohort studies where a defined group of individuals 
(i.e. a cohort) are followed over a specific time period. The incidence of a specific outcome is 
then described in relation to a certain exposure status at the end of follow-up. Register-based 
cohort studies use prospectively collected information (i.e. assess exposure status before any 
information of the outcome is known) and thus become less sensitive to bias than other 
observational studies. 
 
3.3.2 Quasi-Experimental Study Designs 
RCTs are, in clinical research, often considered to be the gold standard for making causal 
inference. However, as in the case of being exposed to SDP, randomization to exposure is not 
always ethical or feasible. For example, in Study I a quasi-experimental approach was used 
to examine individuals exposed to an experimental (sibling exposed to SDP) or control 
condition (sibling unexposed to SDP) determined by nature or other factors outside the 
control of the investigators. Family-based, quasi-experimental studies, as in Study II, make 
use of the fact that the individuals with different genetic relatedness and family relationships 
might differ in both environmental exposure and genetic risk (148).  
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Within siblings and cousins design 
As shown in Study I, quasi-experimental research can address many of the serious limitation 
of traditional observational research by estimating the impact of residual familial 
confounding from unmeasured genetic factors. A confounder is a variable associated with 
both the exposure and the outcome, creating an association that can wrongfully be mistaken 
to be causal. For example, familial confounding can arise in the association between SDP and 
offspring ADHD since mothers provide both in utero exposure to tobacco and part of the 
genetic makeup transmitted to the child. The comparisons of differently exposed full-siblings 
within nuclear families allow for control of unmeasured factors that make siblings similar. 
Similarly, the comparisons of differently exposed full-cousins (offspring of adult full-
siblings) within extended families control for unmeasured factors that make cousins similar 
(148). If an environmental risk, such as SDP in Study I, is causally associated with an 
outcome (e.g. ADHD) the increased risk should be robust to the sibling and cousin design. 
However, if the association is confounded by familial factors (e.g. genetics) the association 
should attenuate along with genetic relatedness, when the sibling and cousin design is 
applied.  
 
Family design 
Within the family design, individuals with different levels of genetic relatedness and 
environmental exposure are compared using the underlying assumption that full-siblings and 
parent-offspring share environment and approximately 50% of their co-segregating genome. 
In line with these assumptions maternal and paternal half-siblings share approximately 25% 
of their genes. Since children, at least historically, tend to continue to live predominantly with 
their mothers following parental separation maternal half-sibling are more similar regarding 
shared environmental exposure than paternal half-siblings (148, 155). Furthermore, family 
studies can utilize the fact that individuals within the extended family, such as cousins, share 
approximately 12.5%, and different levels of exposure to environmental factors. Study II, 
explores the risk of developing SUD among individuals with different genetic relatedness to 
an ADHD proband compared to relatives to matched non-ADHD control subjects.  
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3.4 Study Designs and Subjects 
3.4.1 Study I 
Subjects  
All individuals born in Sweden between 1992 and 2000 were identified from the MBR. 
Individuals with serious congenital malformations, multiple births, still born before or during 
delivery, dead or emigrated before 3 years of age or before 2001, for whom data on mother’s 
identification number was missing or who had received an ADHD diagnosis before 3 years of 
age and with missing values on SDP were excluded. The study population of 768 227 
individuals covering 365 442 full siblings nested within 172 701 families and 155 852 
cousins nested within 52 183 families, were followed up from the age of 3 until diagnosis of 
ADHD, death, emigration, or December 31, 2009, whichever occurred first. 
Exposure  
The MBR provided information on SDP through self-reported prospective information at the 
registration to antenatal care (in pregnancy week 8-12) (149). SDP was measured on a three-
point scale (No SDP = 0, moderate SDP = 1-9, or high SDP = ≥10 cigarettes per day).  
Outcome  
ADHD was defined as an ICD-diagnosis (ICD-10: F90) in the NPR and/or an ICD and DSM- 
IV diagnosis (ICD-10: F90, DSM-IV: 314) in Pastill and/or a prescription with an ATC-code 
for stimulant or non-stimulant ADHD medication (MPH (N06BA04); atomoxetine 
(N06BA09); amphetamine (N06BA01); dexamphetamine (N06BA02) in the PDR. 
Covariates  
Based on previous research (150, 151), measured covariates included sex, birth year (1992-
1994, 1995-1997, and 1998-2000), mother’s parity (1st, 2nd, 3rd, or ≥4th), maternal age at 
childbirth (≤19, 20-24, 25-29, 30-34, or ≥ 35 years), cohabitation with offspring’s father (yes 
or no), highest level of maternal education (≤9 years, 10-12 years or graduate education) and 
mother’s country of birth (Sweden, other Scandinavian countries or others). Since low birth 
weight might be an intermediate factor of the association between SDP and ADHD, the 
analyses were not adjusted for that measure. Pre-pregnancy BMI is considered partly adjusted 
for by maternal education level and could potentially be an intermediate factor, thus it is not 
included as a covariate in the model.  
Study design  
Population based cohort study. Within sibling and cousin design (see 3.3.2). 
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Statistical analyses 
Cox proportional survival analysis, (crude and adjusted for measured covariates) estimated 
the magnitude of the associations between SDP and offspring ADHD at the population level. 
A stratified Cox regression model was used to adjust for the occurrence of dependent data 
(sibling and cousins) by assigning each set of siblings or cousins a separate stratum. The 
models calculated hazard ratios for time to ADHD diagnosis. Robust standard errors adjusted 
the 95% confidence intervals for the presence of familial clustering in the analyses at the 
population level. 
Sensitivity analyses 
The potential modifying effect of birth order (i.e. carry-over effect), bias from outcome 
misclassification in a birth year restricted sibling cohort and generalizability of the sibling 
sample to the entire cohort was tested.  
  
3.4.2 Study II 
Subjects  
In total 62 015 unique ADHD cases were identified, 47 794 patients with an ADHD 
diagnosis were identified from the NPR (ICD-9: 314; ICD-10: F90) and 46 186 ADHD 
patients treated with stimulant or non-stimulant medication for ADHD (methylphenidate 
(N06BA04); atomoxetine (N06BA09); amphetamine (N06BA01); dexamphetamine 
(N06BA02)) at any time between July 2005 and December 2009 were identified from the 
PDR. Patients aged 3-65 years at the time of the first ADHD diagnosis (or first prescription 
of stimulant or non-stimulant medication for ADHD) were included.  
For each case, ten unaffected control subjects were randomly selected. Matching the control 
subjects on sex, birth year, and residential factors ensured equal follow-up time. According to 
well-established procedures for nested case-control designs (152, 153), controls were alive 
and living in Sweden and had not been diagnosed with ADHD at the time of the first ADHD 
diagnosis of the proband. 
Exposure 
Genetic relatedness to ADHD proband or matched control subject in the MGR and the TPR. 
ADHD defined as an ICD-diagnosis in the NPR and/or a prescription with an ATC-code for 
ADHD medication in the PDR (See 3.2.1). 
Outcome 
SUD defined as an ICD-diagnosis in the NPR and/or purchase of any drug with an ATC-code 
used in the treatment of SUD in the PDR (See 3.2.2). 
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Covariates  
Sex, age, education level, psychiatric comorbidity (schizophrenia, bipolar disorder, major 
depression, conduct disorder). 
Study design 
Population-based matched cohort study. Family design (See 3.3.3). 
Statistical analyses  
The statistical analyses were performed using a nested case-control design. Conditional 
logistic regression models adjusted for the fact that associations within the same families 
were not statistically independent of one another. The logistic regression model fitting 
potential confounding factors allowed unequal follow-up time thus minimizing bias 
introduced when individuals in the population registries enter the study at different time 
points (i.e. left truncation). 
Confidence intervals were obtained with a robust sandwich estimator function to adjust for 
non-independence.  
Sensitivity Analyses 
The sensitivity analyses first explored to what extent familial factors for ADHD and SUD 
were shared with other major psychiatric disorders by analyzing subsamples of individuals 
without a diagnosis of schizophrenia and bipolar disorder, depression or conduct disorder 
(CD). Secondly, the sensitivity analyses explored whether the familial association was driven 
by the fact that many families contributed with more than one case-relative pair. This was 
done by selecting and analyzing a sample with only one case-relative pair per family. Thirdly 
the validity of the ADHD diagnosis was studied by analyzing a sample of individuals 
identified as ADHD cases in both the NPR and the PDR. And finally, age differences 
adjusted for education level between different degrees of relatives to cases and controls was 
explored to establish whether this influenced our results.  
 
3.4.3 Study III 
Subjects  
A total of 14 314 individuals, aged 18-59, with an initial prescription of MPH (ATC-code for 
MPH N06BA04), between January 1, 2006, and December 31, 2009 were identified in the 
PDR. Among them, 4870 individuals with a diagnosis of SUD in the NPR or the PDR were 
included in the main analysis. 
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Exposure  
ICD-diagnosis of SUD in the NPR and/or purchase of any drug with an ATC-code used in 
the treatment of SUD in the PDR (See 3.2.2). 
Outcome  
Differences in mean MPH doses between patients with and without SUD. MPH doses were 
stratified into 0-72 mg and >72 mg based on recommendations issued by the British 
Association for Psychopharmacology (recommended maximum dose 100 mg) (10), the 
American Food and Drug Administration (recommended maximum dose 72 mg) (127), and 
the National Institute for Health & Clinical Excellence NICE guidelines (recommended 
maximum dose 60 mg) (11). Also, OROS MPH, the most commonly prescribed MPH 
formulation in Sweden, are only commercially available in multiples of 18 mg. The 
prescribed dose was calculated with annual point estimates every 100 days. The follow-up 
period allowed for times during which medication was discontinued or resumed. Individuals 
were considered to be in active treatment if a prescription was refilled within the number of 
days that the prescription would last according to the text variable on the prescription, plus an 
additional 25% of this time sequence to account for irregularities in dispensing patterns. 
Covariates  
Given the potentially confounding effects of age, sex, SUD subtype, calendar year of the 
initial prescription and comorbid psychiatric diagnoses these covariates were simultaneously 
fitted into the adjusted model.  
Study design 
Population-based cohort study. 
Statistical analyses  
Logistic regression models calculated ORs for dichotomized MPH dose (≤72, >72 mg/day) 
day 365 and 730 after first MPH prescription. Time trends in mean doses in patients with and 
without SUD were tested with linear regression and described in a graph depicting a point 
estimate of the mean dosage every 100 days. 
Sensitivity analysis 
A subsample of the population with doses over 72 mg/day (N=659) was analyzed to test 
whether individuals with MPH doses over 72 mg/day actually picked up doses corresponding 
to those prescribed by the physician. Doses in the PDR on days 300 and 400 were compared 
with the total accumulated dose filled by the pharmacy between days 200 and 400 to explore 
whether the amount of prescribed medication corresponded to the amount of medication 
actually dispensed at the pharmacy.  
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3.4.4 Study IV 
Subjects  
An eligible sample of 4870 individuals with SUD diagnosis in the NPR or the PDR aged 18-
59 years at the first prescription prescribed MPH between January 1, 2006, and December 31, 
2009 was identified from the register linkages. After excluding individuals with inadequate 
follow-up time, treatment discontinuation before day 100, and lack of dose information, 2659 
individuals with a known prescribed MPH dose at day 100 were included in the main 
analyses.  
Exposure  
Patient-related factors were identified based on previous research (135, 138) and measured 
baseline characteristics included sex, age (18-26, 27-39 and 40-59 years of age), SUD 
subtype (alcohol, stimulant or combined) according ICD-8, ICD-9 and ICD-10, and ICD-8, 
ICD-9 and ICD-10 diagnoses for comorbid psychiatric disorders (i.e. schizophrenia, mood 
disorders or anxiety disorders, eating disorders, personality disorders and conduct disorder) 
were identified from the NPR. Treatment-related factors such as the prescribing physician’s 
(sub)specialty (i.e. psychiatry, addiction medicine or other) and MPH doses stratified into six 
different dose categories (≤ 36mg, ≥37mg - ≤54mg, ≥55mg - ≤72mg, ≥73mg - ≤90mg, 
≥91mg - ≤108mg and ≥109mg) were obtained from the PDR. 
Outcome 
Days in active MPH treatment until first discontinuation. Individuals were considered to be in 
active treatment if a prescription was refilled within the number of days that the prescription 
would last according to the text variable on the prescription (plus an additional 25% of this 
time sequence to account for irregularities in dispensing patterns), or within 30 days after the 
last prescription was issued. 
Covariates  
Sex, age, SUD subtype, comorbid psychiatric disorders, and the prescribing physician’s 
(sub)specialty. 
Study design  
Population based cohort study. 
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Statistical analyses 
A Cox regression model, adjusted for individual baseline characteristics, was used to estimate 
time to first treatment discontinuation in relation to six categories of MPH doses. Logistic 
regression models were used in the sensitivity analyses to explore whether base line 
characteristics such as sex, age, SUD subtype, comorbid psychiatric disorders, and the 
prescribing physician’s (sub)specialty (addiction medicine, general psychiatry or other) 
differed between the subsample of individuals who discontinued MPH treatment before the 
initial titration phase of 100 days was completed (early discontinuation) and individuals with 
ongoing MPH treatment day 100. In addition, ongoing MPH treatment at day 100 was 
modeled in a logistic regression model using sex and age as predictors. 
Sensitivity analyses 
The sensitivity analyses explored whether baseline characteristics such as sex, age, SUD 
subtype, comorbid psychiatric disorders, and the prescribing physician’s (sub)specialty 
differed between individuals who discontinued MPH treatment before the initial titration 
phase of 100 days was completed and individuals with ongoing MPH treatment day 100. In 
addition, a possible modifying effect of the above mentioned background factors and a time 
dependent incline in prescribed MPH doses was explored by analyzing subsamples of 
individuals prescribed MPH treatment during different years. Given that the risks of relapse 
into alcohol or drug use might be more pronounced during the first time of abstinence, a 
separate analysis was made to explore if the dose at day 200 was an equally strong predictor 
of treatment adherence as the dose at day 100. 
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4 RESULTS 
4.1 Study I 
Two different quasi-experimental designs (i.e. cousin and sibling comparisons) were used to 
explore the mechanisms through which maternal smoking during pregnancy (SDP) influence 
ADHD. Table 1 show that offspring exposed to maternal SDP were at increased risk for 
ADHD (HRModerateSDP 1.89; HRHighSDP 2.50). The dose-dependent association decreased 
marginally after adjustment for measured covariates but remained statistically significant 
(HRModerateSDP 1.62; HRHighSDP 2.04). The associations were further attenuated in the cousin 
comparisons; that is, after adjustment for all unmeasured factors that are constant within 
extended families (HRModerateSDP 1.45; HRHighSDP 1.69). In the sibling comparisons, the 
associations observed at the population level were completely attenuated and no longer 
statistically significant, indicating that unmeasured familial factors that are constant within 
nuclear families explain the associations (HRModerateSDP 0.88; HRHighSDP 0.84).  
 
 
Table 1 Relative risks of ADHD among offspring exposed to SDP 
a N = 768 227, b N = 720 853 Adjusted for offspring sex, birth year, mother’s parity, maternal age, cohabitation status, maternal highest 
education, and mother’s country of birth. cN = 155 852 Adjusted for offspring sex, birth year, mother’s parity, maternal age, cohabitation 
status. d N = 365 442 Adjusted for offspring sex, birth year, mother’s parity, maternal age, cohabitation status.  
 
 
Sensitivity analyses 
Stratified analyses at the population level showed that the results were robust to the fact that 
second-born offspring were more often exposed to maternal SDP than first-born offspring. In 
addition, the results from the restricted sibling sample were similar to that observed when the 
entire sibling sample was analyzed, indicating limited impact from bias due to 
misclassification. The results in the sibling sample were very similar to those in the entire 
cohort, suggesting adequate external validity. 
 
  HR (95%CI)   
Exposure Crudea Adjustedb Cousinsc  Full siblingd  
No SDP Reference Reference Reference Reference 
Moderate SDP   
(1-9 cigarettes per day) 
1.89 (1.83-1.97) 1.62 (1.56-1.69) 1.45 (1.24-1.68) 0.88 (0.73-1.06) 
High SDP   
(≥10 cigarettes per day) 
2.50 (2.40-2.61) 2.04 (1.95-2.13) 1.69 (1.40-2.04) 0.84 (0.65-1.06) 
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4.2 Study II 
Probands with ADHD were more likely to have been diagnosed with SUD, drug abuse and 
alcohol use disorder compared to age, sex and residency matched non-ADHD controls 
(ORSUD 10.8 95 % CI; 10.5-11.1, ORDrug 19.2, 95% CI; 18.5-19.8, ORAlc 8.3, 95% CI; 8.0-
8.5).  
The risk for SUD increases considerably along with increased genetic relatedness to an 
ADHD proband. Table 2 shows the numbers and percentages of SUD, drug abuse and 
alcohol use disorder for first and second degree relatives to ADHD probands or controls. 
First-degree relatives of ADHD probands were at elevated risk for SUD (ORSUD1st 2.2 and 
1.8) compared to relatives of controls. The corresponding risk in second-degree relatives was 
substantially lower and similar for maternal and paternal half-siblings (ORSUD2nd 1.4 and 1.4). 
The results were robust to adjustments for bipolar disorder and schizophrenia (ORSUD1st 2.2 
and 1.7; ORSUD2nd 1.4 and 1.4), and depression and conduct disorder (ORSUD1st 2.2 and 1.7; 
ORSUD2nd 1.4 and 1.3).  
 
 
Table 2 Risk for SUD in relatives to ADHD probands compared to relatives to controls 
 SUD in relatives	  
ADHD  
N (%)	  
Control 
N (%)	  
ORa 
(95 % CI)	  
1°	  relatives	  
Parent	   7555 (8.9)	   31 748 (4.2)	   2.2 (2.2-2.3)	  
Full sibling	   1805 (3.5)	   9564 (2.0)	   1.8 (1.7-1.9)	  
2°	  relatives 	  
Maternal half sibling	   1098 (5.2)	   6291 (3.9)	   1.4 (1.3-1.5)	  
Paternal half sibling	   1170 (5.1)	   7068 (3.9)	   1.4 (1.3-1.4)	  
a after exclusion of probands and controls with SUD and relatives to probands or controls with ADHD 
SUD=Substance Use Disorder 	  
 
 
 
 
 
 
 
   29 
Sensitivity analyses 
The sensitivity analyses found no significant confounding effect from the fact that 40 300 
families contributed with more than one case-relative pair. The analyses of individuals 
identified as ADHD cases in both the NPR and the PDR showed good validity of the 
ADHD diagnosis. Adjustments for age among relatives to probands and controls and 
differences in parental education level showed no potentially confounding effect of age and 
socioeconomic factors.  
 
4.3 Study III 
A sample of 14 314 adults (including 4870 individuals with SUD) with a prescription of 
MPH between January 1, 2006, and December 31, 2009 was included in the main analysis. 
The mean follow-up period was approximately 550 days in both populations and allowed for 
times during which medication was discontinued or resumed and 93% of the targeted 
population was monitored from date of first prescription to December 31, 2009. Psychiatric 
comorbidity including personality disorders and conduct disorder was more prevalent among 
individuals with comorbid SUD than among individuals with ADHD only. 
One year after start of follow-up, at day 365, 37.1% of individuals with comorbid SUD were 
prescribed MPH doses exceeding 72 mg compared to 20.6% of those with ADHD only (chi-
square p<0.0001). Approximately two years into the treatment, day 730, 44.4% of individuals 
with comorbid SUD were prescribed MPH doses exceeding 72 mg, compared to 22.8% of 
individuals with ADHD only (chi-square p<0.0001). Among individuals with SUD, 7.3% had 
doses exceeding 180 mg/day at day 730, compared to 1.2% of those with ADHD only (chi-
square p<0.0001). Two years after start of follow-up (i.e. day 730), 48% of the individuals 
with ADHD and SUD and 42% of those with ADHD only (chi-square p<0.0001) were still 
actively picking up their prescriptions. The proportion of patients who had been prescribed 
ER formulations was high, both in patients with SUD (86%) and in patients with ADHD only 
(82%) (chi-square p=0.01). 
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Table 3 shows ORs for MPH doses exceeding 72 mg/day in individuals with comorbid SUD 
and ADHD only. Individuals with SUD were at increased risk of exceeding a daily dose of 72 
mg (ORSUDday365 2.12 and ORSUDday730 2.65). A diagnosis of drug abuse (DA), a combined 
diagnosis of both DA and alcohol use disorder (AUD) and a diagnosis of stimulant use 
disorder (SU) significantly increased the risk of exceeding a dose of 72 mg/day (ORDAday365 
2.53, ORDAday730 3.09, ORDA+AUDday365 2.53 and ORDA+AUDday730 2.97, ORSUday365 3.08, 
ORSUday730 3.63). The corresponding risk associated with a diagnosis of AUD only was lower 
(ORAUDday365 1.49 and ORAUDday730 2.01), indicating that SUD subtype and/or severity is 
correlated to MPH dose.  
 
 
Table 3 Logistic regression model of MPH doses exceeding 72 mg/day 
  Day 365 Day 730 
 Dose >72 mg/day Dose >72 mg/day 
  Unadjusted Adjustedb  Unadjusted Adjustedb 
  N (%) OR (95% C.I.) OR (95% C.I.) N (%) OR (95% C.I.) OR (95% C.I.) 
Total 4010 (26)    1826 (31)   
SUD       
No 2610 (21) ref=1 ref=1 1169 (23) ref=1 ref=1 
Yes 1400 (37) 2.28 (1.98-2.64) 2.12 (1.81-2.47) 657 (44) 2.72 (2.21-3.34) 2.65 (2.13-3.30) 
SUD Subtypea          
AUD  473 (29) 1.56 (1.25-1.94) 1.49 (1.19-1.87) 208 (37) 2.00 (1.46-2.73) 2.01 (1.46-2.78) 
DA  453 (41) 2.69 (2.18-3.32) 2.53 (2.03-3.15) 227 (48) 3.14 (2.34-4.21) 3.09 (2.28-4.20) 
AUD+DA 474 (42) 2.77 (2.25-3.40) 2.53 (2.03-3.16) 222 (48) 3.10 (2.31-4.17) 2.97 (2.16-4.09) 
SU 500 (47) 3.48 (2.85-4.25) 3.08 (2.49-3.81) 256 (53) 3.79 (2.86-5.02) 3.63 (2.69-4.91) 
SUD=Substance Use Disorder, AUD=Alcohol Use Disorder, DA=Drug Abuse, SU=Stimulant Use Disorder (.F14 Amphetamine Use 
Disorder and F15 Cocaine Use Disorder) 
 aDiagnosis of /Medication for. . bAdjusted for sex, age, year of initial prescription and psychiatric comorbidity 
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Figure 1 Mean MPH doses over time in individuals with SUD compared to  
individuals with ADHD only 
 
SUD+=Individuals with comorbid Substance use disorder who have been prescribed methylphenidate,  
SUD-=Individuals with ADHD only who have been prescribed methylphenidate 
 
 
Figure 1 shows a small but significant increase in mean doses (1.1 mg/100 days) between 
days 100 and 600 in individuals with ADHD only. The increase of mean doses in individuals 
with comorbid SUD was greater (3.2 /100 days) (p-value for interaction 0.001). In contrast, 
no statistically significant trend in mean doses was observed between days 700 and 1200 
(p=0.30 in the entire population; p=0.21 in individuals with comorbid SUD and p=0.15 in 
individuals with ADHD only).  
 
Sensitivity analysis 
The sensitivity analysis showed that 90 % (95 % CI 87.5 to 92.1) of individuals who were 
prescribed a daily dose of over 72 mg on days 300 and 400 picked up corresponding daily 
doses of over 72 mg at the pharmacy between days 200 and 400.  
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4.4 Study IV 
The adjusted proportional hazard ratios for MPH treatment discontinuation day 101 to 830 
are shown in Table 4. Hazard ratios for treatment discontinuation decrease in conjunction 
with increasing MPH dose up until doses exceeding 72 mg (HR≤36 mg 1.71 (1.33-2.20); HR37-
54mg 1.43 (1.10-1.85); HR55-72mg 1.37 (1.05-1.80); HR73-90mg 1.19 (0.89-1.60); HR≥108mg 1.12 
(0.83-1.51). The results for doses exceeding 72 mg were non-significant compared to the 
reference selected but remained significant compared to other dose categories. A significant 
trend (linear trend, p<0.0001) towards decreased risk for treatment discontinuation in 
conjunction with increased MPH doses is shown across all dose categories. The point 
estimates for doses over 108 mg exceed the estimates for the reference category (90-108mg), 
possibly due to low sample size. Neither a diagnosis of alcohol use disorder alone nor 
individuals with a SUD diagnosis of several drugs in combination were associated with an 
increased risk for treatment discontinuation, whereas individuals with a diagnosis of 
stimulant use disorder were at an 25% increased risk for treatment discontinuation (HRSU 
1.26 (1.06-1.49)). Figure 2 shows a Kaplan Meier survival graph depicting crude treatment 
discontinuation rates among individuals with different MPH doses. 
 
 
 
Table 4 Hazard ratios for MPH treatment discontinuation day 101-830 
 
Na HRb (95% CI) 
Prescribed Dose Day 100   
 ≤36 mg 789 1.71 (1.33-2.20) 
37-54 mg 653 1.43 (1.10-1.85) 
55-72 mg 447 1.37 (1.05-1.80) 
73-90 mg 280 1.19 (0.89-1.60) 
90-108 mg 202 ref=1 
≥108 mg 288 1.12 (0.83-1.51) 
Proportional hazard regression 
MPH=Methylphenidate. anumbers of individuals with ongoing MPH prescriptions day 100.  
bHRs are adjusted for sex, age, SUD subtype, prescribing physician’s (sub)speciality and psychiatric  
comorbidity. 
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Figure 2 Crude MPH discontinuation rates day 101-830 
	    
 
 
Sensitivity analyses 
Males, young individuals and patients receiving their prescriptions from a physician 
specialized in addiction medicine were more likely to experience early treatment 
discontinuation (i.e. before day 100) (ORMale 1.19 95% CI 1.03-1.38; ORAge18-26 1.20 95 % CI 
1.01-1.42; ORAddict 1.28 95% CI 1.01-1.62). Coexisting psychiatric comorbidity or SUD 
diagnosis however did not significantly influence the risk of early treatment discontinuation. 
The dose dependent pattern for treatment discontinuation remained when women were 
analyzed separately and within different SUD subtypes. No time-dependent incline in 
treatment discontinuation among individuals prescribed MPH treatment year 2006-2007 and 
2008-2009 was found (test for linear trend in adjusted model p<0.0001, for both groups), and 
MPH dose at day 200 was an equally strong predictor of treatment discontinuation as dose at 
day 100 (test for linear trend in crude model p=0.02 and in adjusted model p=0.04). 
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5  CONCLUSIONS AND DISCUSSION 
Despite the substantial co-occurrence of ADHD and SUD, we have limited knowledge of 
possible common etiological factors and the safety and effectiveness of pharmacological 
treatment. Contradictive research findings, lack of treatment guidelines and the controversial 
issue of both the origin and treatment of ADHD and SUD put potentially vulnerable patients 
at risk, not only due to increased societal stigmatization, but also because effective treatment 
might be withheld. This thesis aims to expand the knowledge of common risk factors for 
ADHD and SUD and to explore the effectiveness and safety of stimulant treatment when 
ADHD and SUD coexist. 
 
5.1 How are ADHD and SUD Etiologically Related? 
By making use of quasi-experimental family designs, Studies I and II were able to test and 
rule out several different potential explanations for the high overlap between ADHD and 
SUD, arriving at the conclusion that common genetic mechanisms underlie the association.  
Firstly, Study I shows the importance of taking unmeasured familial confounding into 
account before making causal claims in observational research. The previously well-
established increased risk of ADHD in children whose mothers smoked during pregnancy, in 
the literature often interpreted as a causal relationship, was totally attenuated when 
genetically transmitted factors, shared between different family members were taken into 
account. The results suggest that familial factors rather than prenatal environmental 
mechanisms explain the association.  
Secondly, the results in Study II show that pure ADHD (i.e. individuals with ADHD but not 
SUD) predicts pure SUD in relatives (i.e. individuals with SUD but not ADHD) ruling out 
both the possibility of methodological artifacts and harmful effects of ADHD treatment as 
feasible explanations for the prevalent overlap of ADHD and SUD.  
Thirdly, CD is one of the most robust risk factors for SUD (109, 110, 154) and previous 
research indicates that CD drives the association between ADHD and SUD. In other words, 
several studies indicate that the association between ADHD no longer remains after 
adjustment for CD (109-112). However, if and when CD is taken into account, such studies 
are often limited by difficulties in generalizing from childhood to adult populations. Study 
II addresses these alternative explanations and limitations by a) including patients aged 3-65 
years at the time of the first ADHD diagnosis and b) performing sensitivity analyses in a 
subsample excluding all individuals with CD and major depression as well as relatives of 
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cases and controls with ADHD diagnoses and cases and controls with SUD diagnoses, 
showing that pure ADHD in fact predicts pure SUD in relatives even in the absence of CD 
and other common psychiatric comorbidities. These results can be used as further support for 
ADHD as an independent risk factor for SUD.  
Fourthly, in addition to comparing individuals sharing different levels of genetic makeup, 
Study II also attempts to explore the influence of shared environmental influences on the co-
occurrence of ADHD and SUD. Based on the assumption that maternal half-siblings are more 
similar with regard to shared environmental exposures than paternal half-siblings since 
children continue to live predominantly with their mothers following parental separation 
(155), significant differences between different kinds of half siblings would indicate that 
environmental factors were of importance. Given similarities in risk estimates across 
maternal and paternal half-siblings, the results further support underlying genetic rather than 
shared environmental factors.  
Fifthly, after establishing common genetic underpinnings for ADHD and SUD, Study II 
further explored the possibility that pleiotropic effects of genetic risk variants across a broad 
range of diagnostic categories result in a general liability to psychiatric disorder. The results 
show that the familial aggregation pattern remained similar after excluding individuals with a 
diagnosis of bipolar disorder and schizophrenia, suggesting that at least part of the genetic 
overlap is specific for ADHD and SUD.  
Previous sibling comparison studies have been limited by the underdiagnosis of ADHD cases 
(156-158) and potential recall bias and misclassification due to the fact that mothers reported 
on both their own smoking habits and their children’s behavior (156). Study I addressed 
these two critical limitations by a) capturing more than twice as many ADHD cases thus 
allowing for more precise estimates, and b) using information on SDP obtained from the 
MBR and ADHD diagnoses based on clinical diagnosis or medical prescriptions by 
physicians. In addition, cousin comparisons were performed to overcome concerns of 
external validity expressed by researchers who have explicitly hypothesized that women who 
vary in their smoking status across pregnancies are not comparable to all smoking women 
(159).  
 
5.2 Are Stimulant Medication Prescription Patterns Different in Individuals with 
ADHD and SUD Compared to Those with ADHD Only? 
Previous research suggests that stimulant ADHD treatment during childhood and 
adolescence might reduce the risk for future SUD (59, 102). Nonetheless, the most recent 
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meta-analysis by Cunill et al. shows a paucity of evidence for stimulant treatment efficacy 
on both ADHD and SUD related outcomes when ADHD and SUD coexist (7). Study III 
shows that patients with comorbid SUD, two years into stimulant treatment, were 
prescribed approximately 40% higher MPH doses than individuals with ADHD only. Doses 
in both groups stabilized during the first two years of treatment. Individuals with ADHD 
and SUD not only had higher stimulant doses but also higher adherence to pharmacological 
treatment than individuals with ADHD only, across the entire follow-up. 
There might be different explanations to why individuals with ADHD and comorbid SUD 
are prescribed higher stimulant doses compared to those without SUD. On the one hand, the 
dose differences between the two groups may indicate that patients with SUD need higher 
MPH doses to achieve optimal ADHD symptom control. Individuals with comorbid SUD 
might, due to long term drug abuse, have developed a tolerance to central stimulants. An 
increase in tolerance is likely to result in a need for higher doses and prolonged titration 
periods. This would be consistent with two recent randomized controlled trials (160, 161) 
showing significant improvements in both ADHD symptoms and SUD outcomes using 
higher stimulant doses than earlier studies. If accurate, this may explain why previous 
research, limited by MPH doses recommended in current guidelines (mean doses of 62.2 
mg/day) (7), has found little evidence for any beneficial effects of MPH on SUD-related 
outcomes. In line with this hypothesis, Study III show that a diagnosis of drug abuse, a 
combined diagnosis of both drug abuse and alcohol use disorder and a diagnosis of 
stimulant use disorder significantly increased the risk of exceeding a dose of 72 mg/day, 
indicating that SUD severity and/or subtype also may be correlated to MPH dose. On the 
other hand, MPH is a schedule II classed medication (127), and can be used for non-
medical purposes, possibly indicating a more alarming interpretation of the higher doses 
among individuals with SUD. However, the vast majority of individuals with comorbid 
SUD were prescribed MPH ER formulations, associated with low abuse liability. 
Consistent with these result there are research suggesting that rates of abuse and diversion 
of MPH may be lower than expected compared to e.g. opiates or sedatives despite its 
reinforcing effects (162).  
The efficacy of agonist maintenance therapy available for opioid addiction has been 
extensively studied (163), whereas substitution treatment for stimulant use disorders has 
been less investigated and research targeting the direct effect of stimulant medication on 
SUD pathophysiology is as yet inconclusive (164-168). Adequate treatment, more 
specifically adequate dosage, may increase motivation to stay in treatment and prevent 
   38 
relapses to illegal drug use.  
The tendency towards increasing doses during the first two years of treatment, more 
pronounced in individuals with comorbid SUD, may reflect a reluctance to prescribe 
adequate doses due to lack of clinical guidelines. The dose-response relationship of MPH 
on ADHD symptoms is well established (62). Less is known about inter-individual serum 
concentration variability in relation to ADHD symptom control (169), and clinicians are 
left to arbitrarily titrate the medication based on the patient’s subjective response. Given the 
lack of objective assessment procedures, biomarkers or clear treatment guidelines, 
clinicians might, due to fear of misuse, abuse or diversion (125, 170) be reluctant to 
increase doses to optimal levels for individuals with ADHD and SUD.  
Adherence to treatment is one of the most consistent factors associated with a favorable 
addiction treatment outcome. The findings that individuals with comorbid SUD, at any given 
time point during the follow-up had higher adherence to treatment than those with ADHD 
only therefore becomes important. Three years following the initial prescription of MPH, 
45% of patients with ADHD and SUD, compared to 37% of individuals with ADHD only, 
were still actively picking up their prescriptions. There might be several explanations for this, 
and the use of adequate MPH dosage may be one factor that affects motivation to stay in 
treatment and prevent relapses to illegal drug use. 
 
5.3 What Factors Influence Adherence to Stimulant Medication when ADHD and 
SUD Coexist? 
As discussed previously, adherence to treatment is associated with a favorable addiction 
treatment outcome (135) and sometimes used as a proxy for successful treatment outcome 
(e.g., reduction or cession of drug intake) (171, 172). Treatment discontinuation is a costly 
and medically significant problem (129) associated with worse course of both somatic and 
psychiatric disorders (130-132). Previous research is inconsistent regarding factors that might 
influence treatment adherence. Patient age, and in particular the years of transition from child 
and adolescent to adult healthcare services, has consistently been a strong predictor for 
treatment discontinuation for both ADHD and SUD (135, 137-139). Consistent with studies 
investigating treatment discontinuation in individuals with ADHD only, a large meta-analysis 
exploring adherence to addiction treatment in individuals with SUD suggests that even 
though young age is an important demographic factor for treatment discontinuation, other 
patient-related factors might be of limited importance (135). As such, the authors suggest that 
future research should focus primarily on treatment-associated factors (135). Study IV 
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explore if patient related factors such as sex, age, SUD subtype or psychiatric comorbidity 
and treatment related factors such as the prescribing physicians (sub)specialty, or MPH dose 
are associated with adherence to pharmacological treatment. 
Surprisingly, and contrary to the current perception that comorbid ADHD and SUD display 
particularly severe symptoms and impairments (173-176), Study III found that individuals 
with comorbid SUD consistently had greater adherence to pharmacological treatment 
compared to patients with ADHD only. Furthermore, Study IV, more specifically showed 
that higher stimulant doses were associated with higher adherence to treatment, supporting 
the hypothesis that inadequate stimulant doses might at least be part of the explanation for 
the lack effectiveness of stimulant treatment in comorbid SUD (7). 
Consistent with previous research (138, 139, 177), Study IV found that male sex and young 
age increased the risk of early ADHD treatment discontinuation (i.e. before day 100). Since 
several studies show that the discontinuation patterns within these age groups far exceed the 
estimated rate of ADHD persistence (137-139) it might be of particular importance for policy 
makers and healthcare professionals to focus resources on young adults before and after the 
discharge from pediatric services. Young age continued to be discretely associated with 
increased risk for treatment discontinuation after day 100, whereas most measured patient-
related factors such as SUD subtype and psychiatric comorbidity seemed to be less important 
predictors of both long and short-term adherence to treatment. Importantly however, 
individuals with a diagnosis of stimulant use disorders, when analyzed separately and in 
contrast to individuals with both alcohol use disorder and abuse of several drugs in 
combination, showed an increased risk of treatment discontinuation. One explanation to as 
why individuals with a diagnosis of amphetamine and/or cocaine use disorder distinguish 
themselves from other SUD subtypes might be associated with the unstable living conditions 
common among active amphetamine users (178). Socializing with substance using peers, low 
rates of permanent employment and high prevalence of criminal activities are all factors 
known to negatively impact treatment outcome and adherence (178). A more biologically 
oriented theory, supported by imaging studies showing that individuals with stimulant use 
disorder present extremely week dopamine responses to MPH exposure (123, 124), suggest 
that similarities in pharmacokinetic properties of illicit stimulants of abuse and MPH, might 
lead to a more severe form of tolerance to stimulant compounds.  
Treatment with MPH, being a schedule II classed drug (127) is often surrounded by tight 
and rigorous clinical control systems (9, 128), in particular in the presence of SUD. Self-
reported or toxicologically verified relapses violate the treatment agreement and should, 
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according to current guidelines, result in discontinuation of pharmacological treatment until 
SUD remission (9, 128). Adherence to treatment is one of the most consistent factors 
associated with a favorable addiction treatment outcome (135) and the increased adherence to 
MPH treatment in individuals with SUD might, at least in the current Swedish setting, also 
represent a proxy for alcohol and drug abstinence. These hypotheses however need to be 
replicated by future research with the ability to control for diversion of collected prescriptions 
and confounding by indication. 
 
5.4 Limitations and Methodological Considerations 
The studies included in this thesis rely on several assumptions made regarding ADHD, 
SUD and stimulant medication. All the studies must also be viewed in light of the limitations 
associated with observational research in general and each specific study design in particular.  
The assumptions underlying the methods used in Studies I and II rely on the well-established 
theory of meiosis, the type of cell division that produces eggs and sperm and randomly 
distributes alleles from parents to each of their offspring. Accordingly, first-degree relatives 
(i.e. full siblings and parents) share approximately 50% of their co-segregating genes and are 
thereby more genetically similar than second-degree relatives (half-siblings) who only share 
approximately 25% of their co-segregating genes. In addition parents and full siblings are 
assumed to share 100% of their environmental exposures, whereas maternal half-siblings are 
more similar with regard to shared environmental exposures than paternal half-siblings since 
children continue to live predominantly with their mothers following parental separation 
(155). Finally, cousins, being offspring of full-siblings, share approximately 12.5% of their 
cosegregating genes.  
The ascertainment of ADHD cases in Studies I and II was predominantly based on ICD-10 
diagnosis of hyperkinetic disorder and prescribed medication unique for the treatment of 
ADHD. The ICD-10 definition of ADHD is stricter compared with that in DSM-IV, and 
national guidelines for medication of ADHD, issued by the Swedish National Board of health 
and Welfare in 2002, state that medication should be reserved for cases where other 
supportive interventions have failed, indicating that the proxies used for ADHD most likely 
underestimate the incidence of ADHD and identify the more severe ADHD cases. Given that 
these strategies probably could not avoid producing false negatives, bias due to false positives 
is more unlikely. Also, this potential bias would, in the case of Study I, affect the estimates 
on the population level and the sibling and cousin samples in the same direction, diluting the 
risk estimates, driving all associations towards the null. In addition, Study I captures more 
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than twice as many ADHD cases compared to previous sibling comparison studies (157, 158) 
allowing for more precise estimates than previous research.  
Studies exploring exposures or outcomes of SUD and SDP might be limited by the fact that 
these diagnoses can be considered stigmatizing and consequently under diagnosed, 
resulting in bias due to misclassification. In addition, the risk or chance of getting a 
diagnosis might be dependent on cultural norms, legal aspects regarding different drugs of 
abuse and local differences in accessibility to SUD treatment. The probability of an 
individual being misclassified as not having SUD can be considered substantial, thus 
severely limiting the use for register-based research on SUD related outcomes. However, 
there are ways to get around some of these limitations by making use of proxy variables for 
SUD related outcomes. Studies II-IV used prescriptions for medications that are almost 
exclusively used in the treatment of SUD as a proxy for a SUD diagnosis as a complement 
to the ICD diagnosis in the NPR. Of course, these strategies can never fully compensate for 
incomplete register coverage of SUD, but individuals actually diagnosed with SUD 
probably represent a more severe subsample of the diagnoses and the diagnostic specificity 
can be considered high.  
SDP was assessed at the first visit to antenatal care and applied as a proxy for the entire 
pregnancy. As in all observational studies, it is difficult to fully rule out residual confounding 
due to a lack of intact information or misclassification of the exposure. The magnitude of this 
potential bias was considered limited however, since previous studies exploring SDP and low 
birth weight show equally strong associations (47, 179).  
ADHD probands and their relatives might be more exposed to healthcare interventions 
resulting in an obvious risk of detection bias of both ADHD and SUD. Also, given the 
significant time trend in the diagnosis of ADHD (138), the observed association for parents in 
Study II could be overestimated due to under-diagnosis of ADHD in older people and could 
thus explain the higher risk of SUD in parents compared to siblings of ADHD probands. The 
age differences between full and maternal half-siblings could lead to differences in the level 
of the shared environment exposures. Adjustments for parental education however, used as a 
proxy for socioeconomic environment, indicated that potential confounding from differences 
in shared environmental factors across sibling types might be of limited importance.  
Selection bias can arise when the probability of being selected to a specific group is 
associated with either the exposure or the outcome. In Study I younger siblings of ADHD 
cases might be at increased risk of being diagnosed with ADHD compared to a child in a 
family without prior experience of the disorder. In Study II, individuals with ADHD might 
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be at increased risk of being diagnosed with SUD as a consequence of general knowledge of 
the frequent coexistence of both disorders. However, the results were robust to sensitivity 
analysis specifically addressing these potential limitations.  
Although sibling comparison is not confounded by factors shared by siblings, the estimates 
might theoretically be more sensitive to bias due to non-shared confounders than the unpaired 
estimates (159). Given that only discordant sibling pairs are informative and random 
measurement error is not shared by siblings, the within-sibling design might favor selection 
of this bias and consequently increase the attenuation of the observed association between 
SDP and ADHD in offspring.  
In addition, clinicians might be reluctant to prescribe stimulant medications to patients with 
co-occurring ADHD and SUD due to lack of clear clinical guidelines and concerns about 
medication abuse or diversion. This begs the question of whether the registry-identified 
patients with ADHD and SUD who were prescribed stimulant medications comprise a 
representative sample, raising concerns about potential selection bias. Specifically, in the case 
of a general clinical reluctance to prescribe stimulants to dually-diagnosed patients, the 
individuals identified in Studies III and IV could theoretically possess characteristics making 
clinicians more comfortable prescribing stimulants to them. By identifying study participants 
based on dispensed MPH prescriptions, the studies’ design inherits potential limitations to 
generalizability of the results. That is, the design does not exclude the possibility that 
subgroups of patients with coexisting ADHD and SUD may have sought treatment but were 
not prescribed stimulant medication due to specific characteristics of their co-occurring SUD.  
Confounding by indication can be a serious threat to observational pharmacoepidemiological 
studies since the probability of receiving a certain medical treatment can be associated with 
individual prognostic factors for which this particular drug is used. Even for individuals 
affected by the same disorder, the severity of the disorder might influence treatment 
indication, duration and dose. In Studies III and IV register-based data unfortunately did not 
allow for control of ADHD or SUD symptom severity making it hard to fully exclude the 
possibility that different displays of these disorders influenced treatment decisions such as 
dosage. However, since Swedish ADHD treatment recommendations dictate that 
pharmacological treatment is reserved for more severe ADHD cases (9), it seems 
reasonable to assume that individuals included in the studies are among the more severely 
affected ADHD patients. A remaining question is also whether SUD severity per se affects 
the possibility of being prescribed a certain MPH dose. Attempts made to control for this 
possibility indicated that doses were unaffected by SUD subtype and the prescribing 
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physicians (sub) specialty, suggesting limited influence of bias due to SUD symptom 
severity.  
Data on dispensed prescriptions obtained from the PDR used in Studies III and IV cannot 
guarantee that the quantity of medication prescribed and received equals the amount of 
medication actually consumed. Only a strict experimental protocol would allow control for 
this but clinical trials do not allow for the large sample sizes and long follow-up periods 
used in Studies III and IV. Consequently, the observed finding of higher MPH doses in 
individuals with ADHD and comorbid SUD needs to be considered in light of the possible 
diversion of medication. However, although non-medical use and diversion of stimulants 
may be more prevalent in certain populations (170), and despite that diversion of 
prescription opioids has been recently studied (180), the diversion of stimulants has not yet 
been systematically investigated in a Swedish context. 
Treatment with MPH, a schedule II classed medication is controlled (127), and treatment 
guidelines often recommend abstinence from abused substances prior to and during such 
pharmacological treatment (9, 11, 91). As a consequence, individuals with ADHD and 
comorbid SUD might be more closely monitored than individuals with ADHD only. Hence, 
individuals with SUD might, in order to prevent abuse and medication diversion, be subject 
to different or more intense psychosocial interventions and/or monitoring, which in turn 
could explain the proportionally higher adherence to treatment among patients with SUD 
shown in Study III. 
 
5.5 General Conclusions 
This thesis had two overall aims: a) to explore the etiological overlap between ADHD and 
SUD and b) to explore effectiveness and safety of stimulant medication when ADHD and 
SUD coexist. The results from the four studies included in this thesis expand current 
knowledge in several ways. Firstly, Studies I and II show that common genetic 
underpinnings largely explain the well-established overlap of ADHD and SUD. This will 
have several important implications for clinicians, researchers and policymakers. Familial 
history of ADHD needs to be taken into account when assessing risk for future SUD since it 
is not only the individuals themselves, but also their relatives who are at risk for SUD. 
Consequently, with further understanding of the etiological overlap between the two 
disorders, clinicians might be able to target individuals at high risk for SUD at an early stage. 
The findings of common genetic underpinnings for ADHD and SUD may help researchers to 
tailor molecular studies to increase the chances of identifying genetic risk variants shared 
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across ADHD and SUD. This, in turn would generate a better understanding of the 
pathophysiological mechanisms that are common to ADHD and SUD. Even though there is 
mounting evidence that SDP is harmful in many ways, it is essential for policymakers to 
focus on true causal risk factors for ADHD. The results from the current thesis suggest that 
SDP is most probably not one of them.  
Secondly, Study III show that individuals with comorbid SUD were prescribed 
approximately 40% higher stimulant doses that those with ADHD only. Moreover, stimulant 
doses stabilized over time in both groups, with no signs of tolerance. Individuals with 
comorbid SUD rather surprisingly had higher adherence to pharmacological treatment than 
individuals with ADHD only. Furthermore, Study IV showed that higher MPH doses predict 
long-term treatment adherence in individuals with comorbid SUD. The studies, despite being 
of a naturalistic and descriptive nature, provide important information increasing knowledge 
of effectiveness and safety of stimulant treatment in individuals with ADHD who also have 
SUD. The lack of objective assessment procedures, biomarkers or clear treatment guidelines 
gives clinicians little guidance in managing ADHD in the presence of SUD. The concerns 
around the safety of stimulant treatment might make clinicians reluctant to increase doses to 
optimal levels for individuals with ADHD and SUD or result in the withholding of essential 
and effective pharmacological treatment in affected individuals.  
Finally, individuals with ADHD and SUD not only experience great personal suffering and 
functional impairment but are also exposed to a variety of misunderstandings and 
misinterpretations regarding their ADHD symptoms and SUD disorders. Hopefully the 
findings from this thesis can help to increase societal acceptance for ADHD and SUD as 
valid medical diagnoses, reduce the personal and psychosocial stigmatization associated with 
both disorders, and ensure that these individuals receive effective treatment. 
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6 FUTURE IMPLICATIONS  
6.1 Show Me The Genes! 
Molecular genetic studies have so far failed to reproduce the consistently high estimates of 
genetic contribution to several psychiatric disorders, including ADHD (38) found in 
observational research. Based on the findings from this thesis indicating shared genetic 
underpinnings for ADHD and SUD, future molecular genetic studies may identify genetic 
risk variants that are shared across ADHD and SUD in order to generate a better 
understanding of the pathophysiological mechanisms that are common to the two disorders 
and to thereby individualize and optimize future psychosocial and pharmacological treatment.  
 
6.2 The Devil Is In The Details 
A major problem in the clinical management of ADHD and SUD appears when we fail to 
recognize the heterogeneity of these disorders. The importance for future studies to stratify 
participants by more refined SUD and ADHD assessments was highlighted by Covey et al 
showing that smoking cessation responses to MPH, depend both on ADHD subtype and 
severity of nicotine dependence (181). The current classification systems (i.e. DSM-IV and 
ICD-10) are categorical, assigning individuals to a discrete clinical entity (case yes/no). 
However, genetically informed research (182) as well as the most recent diagnostic 
instruments (71) support a more continues approach where ADHD and SUD symptoms are 
best viewed along a continuous spectrum towards increased disorder severity. Increased 
focus on ADHD and SUD endophenotypes (refined neural or behavioral entities more 
proximal to the etiology of the original phenotype (183)) might be an important 
complement to DSM or ICD definitions. This approach might also increase the chances of 
identifying genetic variants involved in disease etiology, improve the understanding of the 
complex clinical picture, the liability for certain comorbidities and individual variations in 
response to pharmacological treatment (183, 184). Current research has as yet failed to 
identify any distinct behavioral or neurocognitive endophenotypes of ADHD and SUD, but 
this approach remains very useful in managing and tailoring individual treatment programs in 
a clinical setting.  
 
6.3 Medical Treatment Or Just Drugs For People with Addiction? 
The rationale behind maintenance therapy (e.g. methadone for opioid dependence) is to 
prevent relapse into active illicit drug use by providing orally administered compounds, 
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with mechanism of action similar to but with lower addictive potential, than the drug of 
abuse (168, 185). An important question that deserves further investigation is whether MPH 
primarily targets ADHD symptoms or modulates the pathophysiology of SUD directly, or 
both. Based on efficacy of agonist maintenance therapy available for opioid (163, 186) and 
nicotine addiction (187), several researchers have hypothesized that medically prescribed 
psychostimulants such as MPH might reduce withdrawal and craving, as well as the 
reinforcing effects of amphetamine or methamphetamine (160, 164-167, 188, 189). 
However, the direct effect of stimulant medication on SUD pathophysiology is as yet 
inconclusive (185). The results from Studies III and IV indicate that adequate treatment, or 
more specifically adequate dosage, might increase motivation to stay in treatment. Future 
research should use more detailed information on ADHD and SUD and outcome proxies for 
relapses to illegal drug use or diversion of stimulant medication to further explore the 
potential for MPH treatment of SUD.  
 
6.4 Can I Trust You? 
Despite several epidemiological studies suggesting possible protective effects of ADHD 
medication on future development of SUD (59, 102), there are still some lingering concerns 
about harmful effects of stimulant treatment stemming primarily from findings of animal and 
imaging studies (99, 103, 104).  
In addition, MPH can be used for non-medical purposes, by healthy students without 
ADHD to stay awake (190), by athletes to enhance performance (191) and for recreational 
purposes to gain high or increased sociability (192). The studies included in this thesis 
cannot rule out the possibility that the prescribed medication was used in another way than 
was the intention of the prescribing physician.  
IR formulations of MPH designated for oral use that are administered intravenously affect 
brain areas involved in the reward system, resulting in reinforcing experiences almost 
identical to those of cocaine (99, 103, 104). This risk could make clinicians fear or suspect 
that patients may feign ADHD symptoms in order to obtain stimulant medication (126). 
Consequently the extent and nature of non-medical use, abuse and diversion, becomes an 
important area for future research. It is crucial to explore specific factors associated with 
abuse and diversion of stimulants to be able to target and protect vulnerable individuals. This, 
in turn, will ensure that adequate treatment interventions are aimed at individuals who need 
and benefit from them, increasing the security and validity of stimulant medication when 
ADHD and SUD coexist. 
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7 SVENSKSPRÅKIG SAMMANFATTNING 
Trots att det är välkänt att personer med ADHD har en ökad risk för att drabbas av skadligt 
bruk eller beroende av alkohol eller droger (Substance Use Disorder, SUD), vet vi 
förhållandevis lite om hur olika ärftliga och miljömässiga faktorer bidrar till denna 
riskökning. Centralstimulerande medicin, till exempel methylfenidat (MPH), rekommenderas 
som säker och effektiv behandling vid ADHD, men vi har relativt lite kunskap kring effekt 
och säkerhet av sådan behandling hos personer som även har SUD. Det finns idag få 
konsekventa riktlinjer för hur dessa ofta utsatta patienter bäst ska behandlas. 
I Studie I och II undersöker vi olika förklaringar till den höga samsjukligheten mellan 
ADHD och SUD. Den första frågan vi ställer är om rökning under graviditet (Smoking 
During Pregnancy, SDP) orsakar ADHD eller om det starka sambandet man sett i tidigare 
studier istället kan förklaras av att ärftliga faktorer kan påverka både risken för att röka under 
graviditeten och risken för ADHD. Studie I visar att risken för ADHD inte kvarstår när man 
jämför syskon vars mödrar rökt under den ena graviditeten men inte den andra. Vi tolkar 
resultaten som att genetiska faktorer snarare än själva rökningen skapar den riskökning man 
ser när obesläktade individer jämförs. I Studie II som är en familjestudie, undersöker vi flera 
olika förklaringar till den ökade risken för SUD hos personer med ADHD. Genom att 
jämföra risken för SUD hos släktingar till personer med, respektive utan ADHD kan man 
undersöka om den höga samsjukligheten förklaras bäst av en överlappande symtombild, 
skadliga effekter av ADHD medicinering eller delade genetiska och miljömässiga faktorer. 
Det visade sig att risken för SUD är högre ju närmare släkt man är med en person som har 
ADHD. Detta stämmer bäst överens med en gemensam genetisk förklaringsmodell.  
I Studie III och IV jämför vi förskrivningsmönstret av MPH hos personer med och utan 
SUD. Vi undersöker hur MPH doserna utvecklas över tid och om man kan se några tecken på 
successivt ökande doser i någon av grupperna. Studie III visar först och främst att patienter 
med SUD förskrivs högre doser, men även att de fortsätter att hämta ut sina recept under en 
längre tid än patienter utan SUD. I Studie IV tittar vi närmare på hur olika patient- och 
behandlingsrelaterade faktorer påverkar hur länge personer med SUD stannar kvar i MPH 
behandling.  
Att vara drabbad av både ADHD och SUD kan leda till många olika typer av problem, ofta 
kopplat till ett stort lidande både för de drabbade och deras anhöriga. Personer med både 
ADHD och SUD kan ha svårt att finna sig tillrätta inom hälso- och sjukvården och de 
psykosociala konsekvenserna av denna samsjuklighet kostar samhället stora summor pengar. 
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Med den här avhandlingen vill vi öka förståelsen och acceptansen för ADHD och SUD som 
valida och behandlingsbara tillstånd. Vi hoppas att ökade kunskaper om de bakomliggande 
orsakerna till ADHD och SUD ska leda till att samhällets resurser används där de kan göra 
mest nytta. Förhoppningsvis kan även resultaten i denna avhandling bidra med en pusselbit 
till den långsamt växande kunskapen kring behandling av personer med samtidig ADHD och 
SUD. 
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